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Abstract 
Background: Duplex ultrasound is performed routinely for vascular mapping prior to 
hemodialysis arteriovenous fistula (AVF) creation but cannot visualize the central 
vasculature. Ferumoxytol, an iron oxide nanoparticle, provides an alternative to 
gadolinium contrast for MR angiography for safe use in chronic kidney disease 
(CKD). 
Purpose: To assess the clinical utility of ferumoxytol-enhanced MR angiography for 
vascular mapping before upper limb AVF creation in CKD compared with Duplex 
ultrasound. 
Materials and Methods: In a prospective comparative study (ClinicalTrials.gov:  
NCT02997046) from December 2016 and August 2018, participants with CKD 
underwent ferumoxytol-enhanced MR angiography and Duplex ultrasound. Two 
independent readers evaluated vessels for diameter, stenosis or occlusion, arterial 
disease, and central stenosis. Interclass correlation coefficients (ICC) and Bland-
Altman plots assessed intra- and inter-reader variability. Based on accepted standards 
for AVF creation, an algorithm was developed to predict AVF outcome based on 
imaging findings. Multivariable regression models used AVF success as the 
dependent variable and age, sex, and Duplex ultrasound or ferumoxytol-enhanced MR 
angiography findings as the independent variables. 
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Results: 59 participants with CKD (mean age 59±13 years, 30 women) were 
evaluated. A total of 51 fistulas were created, of which 24 (47%) were successful. 
Ferumoxytol-enhanced MR angiography showed excellent inter- and intra-reader 
repeatability (ICC 0.84-0.99) for all variables assessed. In addition to identifying 15 
central vasculature stenoses, ferumoxytol-enhanced MR angiography characterized 
88/236 (37%) of the arterial sections examined as unsuitable for AVF creation 
compared with 61/236 (26%) with Duplex ultrasound  (P=0.01). Ferumoxytol-
enhanced MR angiography independently predicted AVF success in models including 
[OR: 6.5 (95% CI 1.7-25); P=0.006] and excluding [OR: 4.6 (95% CI 1.3-17); 
P=0.02] the central vasculature. 
Conclusion: In addition to the identification of central vessel pathology, ferumoxytol-
enhanced MR angiography showed peripheral arterial disease not recognized with 
Duplex ultrasound and predicted the outcome of arteriovenous fistula surgery better 











Compared with Duplex ultrasound, ferumoxytol MR angiography had superior 
detection of central vein stenosis and arterial disease that correlated with 
outcomes of arteriovenous fistula surgery for hemodialysis. 
 
Key results: 
- In 59 participants with chronic kidney disease, ferumoxytol-enhanced MR 
angiography identified 15 central vessel stenoses and characterized 37% of arterial 
sections as unsuitable for arteriovenous fistula creation compared with 26% for 
Duplex ultrasound (P=0.01). 
- Ferumoxytol-enhanced MR angiography independently predicted successful fistula 
outcome for models including [OR: 6.5; P=0.006] and excluding [OR: 4.6; P=0.02] 
central vasculature. 
-Ferumoxytol-enhanced MR angiography showed excellent inter- and intra-reader 












AVF: arteriovenous fistula 
CE: contrast-enhanced 
CKD: chronic kidney disease 
CVS: central vein stenosis 





















































 Preoperative sonographic mapping of arm vessels is essential for creating 
permanent hemodialysis access and used for both arterial and venous evaluation to 
optimize arteriovenous fistula (AVF) placement for avoiding unsuccessful surgery1-3. 
But Duplex ultrasound is limited by an inherent operator-dependence, the inability to 
provide direct evidence of central stenosis4 and the lack of image manipulation and 
reconstruction to inform the surgeon about vascular anatomical course and tortuosity. 
 Contrast-enhanced MR angiography provides excellent visualization of both 
central and upper extremity vessels5,6. However, the risk of nephrogenic systemic 
fibrosis in advanced chronic kidney disease (CKD) curtailed its use in arteriovenous 
access planning 7. Nonetheless, suspected central stenosis may still require 
angiography of the central vessels. An alternative option of traditional iodinated 
contrast-based CT angiography risks nephrotoxicity in patients with residual renal 
function. 
 Ferumoxytol has been increasingly used for MR angiography, particularly for 
patients with CKD8-10. Ferumoxytol is an ultra-small paramagnetic iron oxide 
embedded in a carbohydrate coating11 originally designed as a contrast agent for 
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MRI12. However, a strategic decision to license the drug as a therapeutic iron 
supplement eclipsed its use as an MRI contrast agent. A large molecular weight of 
750kD11 for ferumoxytol delays contrast extravasation, allowing slow administration 
or application before the patient is transferred to the MRI suite. The glomerulus does 
not filter ferumoxytol.  Removal of ferumoxytol occurs via circulating macrophages 
with the remaining iron oxide particles taken up by the reticuloendothelial system of 
the liver, spleen and bone marrow. Given its half-life of approximately 15 hours,13 
ferumoxytol allows enhancement of both the arterial and venous vasculature without 
the need for bolus timing. 
 Our study hypothesis was that ferumoxytol-enhanced MR angiography is 
superior to Duplex ultrasound for AVF planning as a) it can diagnose central stenosis 
and b) it can precisely assess arm vessels anatomy and identify abnormalities. To test 
our hypothesis we compared the two modalities using anatomical parameters 
predictive of fistula outcome in participants with CKD.  
 
Materials and Methods 
Study protocol 
 This was a prospective comparative single center study conducted between 
December 2016 and August 2018. The study protocol 
(http://dx.doi.org/10.36399/gla.pubs.215112) was approved by the institutional review 
board (Research Ethics Committee reference: 16/NS/0099) and registered with the 
ClinicalTrials.gov (NCT02997046). The study was funded by the Glasgow renal and 
transplant unit endowment fund and ferumoxytol was supplied by AMAG 
Pharmaceuticals free of charge. The authors had control of the data and the 
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 Participants with CKD (≥18 years of age) requiring vascular mapping before 
creation of an autogenous upper arm AVF were eligible for enrollment. Consecutive 
patients with CKD attending the outpatient renal clinics were screened for eligibility. 
Exclusion criteria were a) frail, elderly or participants with multiple or serious co-
morbidities, b) standard contraindications to MRI and c) history of allergic reaction to 
any intravenous iron product, multidrug allergies, conditions associated with iron 
overload, and participants with asthma. 
 
Study procedures 
 All participants underwent ferumoxytol-enhanced MR angiography and 
Duplex ultrasound on the same day using a standardized protocol (online 
Supplemental Material). Ultrasound mapping was performed with a Philips iU22 
color Duplex scanner (Philips Healthcare, Bothell, WA) (online Supplemental 
Material). 
 Ferumoxytol-enhanced MR angiography was performed on a 3.0 T Prisma 
MRI scanner (Magnetom, Siemens Healthineers, Erlangan; Germany) with phased-
array imaging coils. To reduce scanning time only one arm was assessed, unless there 
was uncertainty on the side of AVF creation, in which case both arms were scanned. 
The participants were positioned supine in the magnet with the arms lying alongside 
the body. The arm of interest was placed as close to the magnet center as possible, 
and the other arm was placed close to the side of the magnet bore. For imaging of the 
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central vasculature, upper and the lower arm, we used different overlapping fields of 
view to minimize image distortion (Movies S1, S2, S3 - online Supplemental 
Material). For analysis of the vessels, steady state high-spatial-resolution 3D FLASH 
acquisitions were obtained after administration of the full dose of ferumoxytol. 
Acquisition parameters for the post-contrast MR angiography included repetition time 
(TR) of 2.88 msec and echo time (TE) of 1.04 msec (Table S1 – online Supplemental 
Material). Ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Waltham, MA) was 
infused intravenously at a dose of 3mg/kg (up to a maximum of 300mg) based on 
preliminary data from feasibility14 and dose-finding15 studies. Ferumoxytol was 
diluted in sodium chloride 0.9% (1:4 dilution factor) and delivered by an MRI-
compatible infusion pump for precise control over at least 15 minutes. Average scan 
duration was 20 minutes (or 30 minutes for both arms) and participants were observed 
for a minimum of 30 minutes following termination of ferumoxytol infusion. 
 
Image analysis 
 Two independent readers with more than 3 years of experience in 
cardiovascular MR imaging (S.S., nephrologist with expertise in hemodialysis 
vascular access and A.T., interventional radiologist) assessed the ferumoxytol-
enhanced MR angiography and one reader (S.S.) the Duplex ultrasound (standard 
technique). To assess intra-reader agreement for the ferumoxytol-enhanced MR 
angiography, both readers repeated the analyses within a time interval of >30 days to 
avoid recall bias. Readers were blinded to all clinical information, Duplex ultrasound 
results and AVF outcome during analysis. 
 For comparative analysis arterial and venous cross-sections (4 of each) were 
selected at specified locations. We analyzed 472 cross-sections for each imaging 
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technique (8 sections per participant). These circular cross-sections were placed in the 
radial artery at wrist, mid-forearm and elbow, brachial artery at elbow, cephalic vein 
at wrist, mid-forearm and elbow, and basilic vein at elbow (Figure 1). Internal 
diameter measurements of the arteries and veins, as well as depth of the anterior wall 
of the vein to the skin surface, were performed. In non-circular vessels, the maximum 
estimated vessel diameter was used for analyses. For estimation of vein diameter, the 
measurement obtained with the tourniquet was used as this is thought to more closely 
approximate to the size of the arterialized vein after fistula formation16. 
   
Algorithm to predict AVF outcome 
 As part of routine clinical practice, most patients in our center have 
preoperative Duplex ultrasound before AVF creation. The surgeons creating the 
fistulas had this information available, but were blinded to both the ferumoxytol-
enhanced MR angiography and Duplex ultrasound that were performed separately as 
part of the study. 
 Based on accepted anatomical criteria for AVF creation3,17, an algorithm was 
formulated to predict AVF outcome relying on MR angiography or US findings 
(Figure 2). The parameters included in the algorithm were a) vessel diameter, b) 
patency, and the presence of c) arterial disease or d) central stenosis. A minimal 
arterial diameter of 2.0 mm and a venous diameter of 2.5 mm were predictive of a 
successful AVF outcome. Arterial or venous stenosis or occlusion and the presence of 
arterial disease were predictive of poor outcome. Arterial disease was defined as 
extensive calcification or monophasic flow on Duplex ultrasound, and narrowed 
arteries with luminal interruptions on ferumoxytol-enhanced MR angiography. 
Subclavian artery and central vein stenoses were predictive of poor outcome in the 
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unilateral arm. For brachio-cephalic fistulas, cephalic arch stenosis was also 
predictive of poor outcome. 
 Arteriovenous fistula outcome was defined using US surrogates for maturation 
and clinical use (online Supplemental Material). 
 
Data analysis  
 Descriptive statistics are expressed as means ± SD or absolutes and 
percentages. Interclass correlation coefficient (ICC) with 95% CI using two-way 
mixed effects models were performed to test intra- and inter-reader consistency of 
agreement and Bland-Altman plots18 of inter-reader variability were created. ICC was 
interpreted as follows: <0.40 poor, 0.40–0.59 fair, 0.60–0.74 good, ≥0.75 excellent19. 
Three binomial logistic regression models were created with successful AVF outcome 
as the dependent variable and age, sex, and Duplex ultrasound (model 1), or 
ferumoxytol-enhanced MR angiography of central and peripheral vessels (model 2) or 
ferumoxytol-enhanced MR angiography of peripheral vessels (model 3) as the 
independent variables. To compare our models, the Akaike’s Information Criterion 
(AIC) was used as a measure of the models' fit. 
 The Stata Statistics Package (Stata/SE, version 15.0; StataCorp LLC) was 




 Between December 2, 2016, and August 20, 2018, 302 participants were 
screened and 65 were enrolled (Figure 3). Of the 237 subjects who were excluded, 
158 were found to be ineligible for the study. The reasons for exclusion in these 158 
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subjects are shown in Figure 3 and Table S2 (online Supplemental Material). In total, 
59 participants (mean age 59 ± 13 years; 30 women; 27% with diabetic nephropathy) 
underwent study specific mapping protocols (Table 1). Median follow-up after AVF 
creation was 22 (interquartile range 18 - 27) months. No adverse events occurred 
related to ferumoxytol infusions, and there were no systematic changes in blood 




 The overall inter-reader agreement for ferumoxytol-enhanced MR 
angiography derived measurements of the arterial diameter (ICC: 0.90; 95% CI: 0.87, 
0.93), venous diameter (ICC: 0.84; 95% CI: 0.78, 0.88), and vein depth from skin 
surface (ICC: 0.92; 95% CI: 0.89, 0.94) was excellent across all vascular sections 
(Table S3 – online Supplemental Material). Twenty participants (aged 58 ± 12 years; 
11 women; 31% with diabetic nephropathy) were selected at random for intra-reader 
agreement, interclass coefficients were between 0.91 – 0.99 for all parameters, 
indicating excellent agreement (Table S3 – online Supplemental Material). There 
were no fixed or proportional biases, and >95% of differences consistently fell within 
acceptable limits of agreement for all vessel sizes and vein depths from skin surface 
(Figure 4). 
 
Predictors of AVF outcome 
 We tested three independent variables in each of the binomial logistic 
regression models used for multivariable analysis: age, sex, and either Duplex 
ultrasound (model 1), ferumoxytol-enhanced MR angiography of central and 
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peripheral vessels (model 2), or ferumoxytol-enhanced MR angiography of peripheral 
vessels (model 3). In univariable analysis for AVF outcome (success vs failure) 
ferumoxytol-enhanced MR angiography of central and peripheral vessels [odds ratio 
(OR) 5.1 (95% CI 1.5-17); P=0.008], and ferumoxytol-enhanced MR angiography of 
peripheral vessels [OR 4.2 (95% CI 1.2-15); P=0.03] predicted a successful outcome. 
Using multivariable analysis, ferumoxytol-enhanced MR angiography of central and 
peripheral vessels [OR 6.5 (95% CI 1.7-25); P=0.006], and ferumoxytol-enhanced 
MR angiography of peripheral vessels [OR 4.6 (95% CI 1.3-17); P=0.02] were 
independent predictors of successful AVF outcome. There was no significant 
association between age (P=0.14), sex (P=0.77), or Duplex ultrasound (P=0.14) and 
outcome (Table 2). The AIC was 72, 66 and 69 for models 1, 2 and 3 respectively, 
showing that model 2 better predicted AVF outcome. 
 Ferumoxytol-enhanced MR angiography and Duplex ultrasound equally 
identified peripheral vein sections unsuitable for fistula creation, but ferumoxytol-
enhanced MR angiography classified more arterial sections as unsuitable for fistula 
attempt predominantly based on diameter criteria (Table 3). Ferumoxytol-enhanced 
MR angiography detected central vein stenosis (CVS) in 7/59 (12%) participants 
(Movie S4 - online Supplemental Material). Cephalic arch stenosis was present in 
6/59 (10%) and subclavian artery stenosis in 2/59 (3%) participants (Table 3 and 
Figure 5). Five (71%) of patients with CVS had previous central venous 
catheterizations for dialysis. Ferumoxytol-enhanced MR angiography better assessed 
vessel course and tortuosity but both imaging modalities depicted other anatomical 
characteristics (such as branches or vein depth from skin surface) (Table 3). From the 
27 unsuccessful AVF surgeries, 7 (26%) could have been avoided based on the 




 Arteriovenous fistula failure is common and invariably associated with 
preexisting anatomical problems of the inflow and outflow circuit. Ferumoxytol-
enhanced MR angiography provided high quality peripheral vascular mapping in 
participants with CKD referred for arteriovenous fistula creation with accurate 
depiction of the central vasculature. Compared with Duplex ultrasound, ferumoxytol-
enhanced MR angiography better predicted successful fistula outcome (OR 6.5; 
P=0.006) and identified small arteries unsuitable for fistula creation not recognized 
with Duplex ultrasound (37% vs 26%; P=0.01). In addition, ferumoxytol safely 
imaged predialysis patients without concerns for iodine or gadolinium contrast 
toxicity.  
 In our study, more than a third of participants had at least one previous central 
venous catheterization for dialysis, 12% had CVS and another 10% cephalic arch 
stenosis. Our rates are comparable with other studies, such as Oguzkurt et al., who 
reported 16% angiographically-proven CVS in dialysis patients with temporary 
catheters20 and Wang et al., who reported 9% clinically noticeable CVS in dialysis 
patients21. Central vein stenosis is most commonly related to prior central catheters 
and can occur due to trauma from catheter insertion, stagnation of blood at the 
catheter insertion site, and turbulent blood flow during hemodialysis22. Our results 
showed 71% of CVS associated to previous catheters but it was conspicuously seen in 
participants without prior catheter use, and without the presence of non-dialysis risk 
factors, such as transvenous pacemakers and previous admission to the intensive care 
unit.  
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 Our results suggest that for the distinction of small diameter arteries (< vs >2.0 
mm), ferumoxytol-enhanced MR angiography had a better discriminatory power than 
Duplex ultrasound, whereas for the distinction between small diameter veins (< vs 
>2.5 mm), there was no difference in diagnostic performance. Ferumoxytol-enhanced 
MR angiography has excellent spatial resolution providing a more precise estimate of 
the vessel lumen, whereas Duplex ultrasound is operator-dependent and susceptible to 
the presence of calcification. This likely explains why the difference was only noted 
in the arteries and not in the veins. Patient positioning (seated vs lying) or the lower 
temperature in the MRI suite could also have contributed in the discrepancy, but the 
effect of these factors (if any) is impossible to quantify. 
 In the wake of our findings, the adoption of ferumoxytol-enhanced MR 
angiography in clinical practice could increase the number of successful first-time 
fistulas and thereby reduce the burden of repeated procedures. Nonetheless, Duplex 
ultrasound remains the screening tool of choice in the initial workup of most patients 
before fistula creation due to its ease of use, lower cost, and applicability to almost all 
patients. Ferumoxytol-enhanced MR angiography could be reserved for patients with 
risk factors for venous complications, peripheral arterial disease, previous failed 
accesses or borderline vessels in Duplex ultrasound. This is highlighted in the recent 
European Society for Vascular Surgery (ESVS)2 and Kidney Disease Outcomes 
Quality Initiative (KDOQI)23 clinical practice guidelines for vascular access, which 
recommend various imaging studies to evaluate the suitability of peripheral vessels 
and central veins for occlusion.  
 In June 2009, ferumoxytol was approved for parenteral treatment of iron 
deficiency anemia in patients with CKD24 and in February 2018, a broad label was 
granted across all conditions associated with lack of iron in adults who were intolerant 
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of or had an inadequate response to oral iron25. Ferumoxytol is less immunogenic 
compared to other parenteral iron preparations with minimal labile free iron release.11 
But in some patients (1 to 3%) the iron release can cause a constellation of symptoms 
termed a Fishbane reaction. In 2015, the U.S. Food and Drug Administration (FDA) 
issued a black-box warning for ferumoxytol26. Based on 79 reports of spontaneous 
adverse events relating to therapeutic use (18 fatal), the FDA warned of rare but 
serious hypersensitivity reactions including anaphylaxis. New therapeutic prescribing 
recommendations included dilution, infusion over 15 minutes (in contrast to the 
originally advocated bolus injection over 17 seconds), and hemodynamic monitoring 
up to 30 minutes after infusion. While this is applicable for the therapeutic dose of 
510mg (approximately 7mg/kg for a 70kg adult), the prorated infusion time for the 
diagnostic dose of 3mg/kg would be about 6.5 minutes, while still staying within the 
recommended FDA limits. A multicenter safety report on diagnostic use of 
ferumoxytol in MRI from 11 institutions worldwide (including our center), 
demonstrated no serious adverse events and few (<2%) minor adverse reactions 
following 4,240 ferumoxytol injections27 using various infusion rates. 
 Ferumoxytol-enhanced MRI has been used in small CKD studies for a 
plethora of applications: diagnosis of central venous occlusion28, assessment of 
kidney transplant vasculature29,30 and autogenous hemodialysis arteriovenous 
fistulas31, vascular mapping for access planning or transplantation32 and transcatheter 
aortic valve replacement33, venography in pediatric34 and adult patients.35 Currently, 
ferumoxytol-enhanced MRI is being tested for detection of coronary artery stenosis 
(NCT02954510). In all studies, ferumoxytol-enhanced MR angiography had good 
performance with comparable or superior image quality, along with reduced flow 
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artifacts and scanning time compared with conventional digital subtraction 
angiography and non-enhanced or gadolinium-based MR angiography. 
 Our study has limitations. First, we did not examine internal jugular and 
subclavian vein waveforms with Duplex ultrasound to indirectly predict the presence 
of central vein stenosis. However, this is time-consuming and technically difficult. 
Second, our study is a single center experience reflecting local referring patterns and 
practices; nevertheless the arterial and vein diameter criteria used in our predictive 
models are universally acceptable17. Third, the sample size in our study was relatively 
modest with respect to absolute participant numbers, but many vascular sections 
(approximately 500) were analyzed. There are also limitations pertaining to 
translation of our study protocol to clinical practice. For example, ferumoxytol is not 
as yet licensed as a contrast agent for MRI and it is only used off-label by clinicians 
and researchers. Emerging issues with trace gadolinium retention in biologic 
tissues36,37 have given rise to new controversies about the use of gadolinium-based 
contrast agents in MRI and have generated calls for new contrast agent classes. To 
date, a growing number of imaging studies with ferumoxytol are underway. 
 In conclusion, our results demonstrated that ferumoxytol-enhanced MR 
angiography is a useful technique for vascular mapping before hemodialysis access 
creation to minimize unnecessary surgical procedures. Ferumoxytol-enhanced MR 
angiography is fast, operator-independent, reliable in the detection of central vein 
stenosis, and more accurate for visualization of the arm vessels compared with 
Duplex ultrasound. A randomized study of ferumoxytol-enhanced MR angiography 
vs Duplex ultrasound with appropriate stratification is needed to identify the patients 
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Table 1. Baseline characteristics of the 59 study participants 
Age (y), mean (SD) 59 (13) 
Men, n (%) 29 (49) 
Race, n (%) 
   White 49 (83) 
   Asian 9 (15) 
   Black African 1 (2) 
Body weight (kg), mean (SD) 74 (17) 
Body mass index categories, n (%) 
   <18.5 5 (9) 
   18.5 - 24.9 16 (27) 
   25 - 30 18 (30) 
   >30 20 (34) 
Cause of end-stage kidney disease, n (%) 
   Diabetes 16 (27) 
   Glomerulonephritis 13 (22) 
   Renovascular 7 (12) 
   Polycystic kidney disease 6 (10) 
   Unknown 7 (12) 
   Othera 10 (17) 
Laboratory values at time of MRI 
   Hemoglobin (g/L), mean (SD) 107 (17) 
   Creatinine (mg/dL), mean (SD)b 5 (2) 
   Estimated glomerular filtration rate (mL/min/1.73m2), mean 
(SD)b 
12 (3) 
Chronic kidney disease stage, n (%) 
   Stage 4 5 (8) 
   Stage 5 - non-dialysis 33 (56) 
   Stage 5 - dialysis 21 (36) 
Dose of ferumoxytol given (mg), mean (SD) 227 (48) 
At least one previous arteriovenous access, n (%) 9 (15) 
At least one previous central venous catheterization, n (%) 21 (36) 
 
aObstructive uropathy (n=3), Pyelonephritis (n=2), Tubulointerstitial nephritis (n=2), 
Cyclosporine toxicity (n=2), Congenital dysplasia (n=1) 


















(Fe MR angiography central 
plus peripheral vessels) 



















Age, per year 1 (0.9 – 1) 0.28 1 (0.9 – 
1) 
0.23 1 (0.9 – 1) 0.21 1 (0.9 – 1) 0.14 
Sex 1.3 (0.4 – 4) 0.65 1.2 (0.4 – 
3.9) 
0.77 1.1 (0.3 – 
3.8) 
0.85 0.9 (0.3 – 3.2) 0.86 
US mapping 2.3 (0.7 – 
7.4) 
0.17 2.5 (0.7 – 
8.4) 
0.14   




Fe MR angiography (central plus 
peripheral vessels) 
5.1 (1.5 – 17) 0.008   6.5 (1.7 – 25) 0.006 
Fe, ferumoxytol-enhanced
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Table 3.  Anatomical lesions and variants identified in 236 vascular cross-sections 








Unsuitable arterial sections 
   Small diameter 72 48 
   Presence of arterial disease 11 11 
   Stenosis, occlusion 5 2 
   Absence 0 0 
Unsuitable vein sections 
   Small diameter 106 107 
   Stenosis, occlusion 30 5 
   Absence 1 7 
Central stenosis 
   Subclavian artery 2 - 
   Cephalic arch 6 - 
   Subclavian vein 4 - 
   Brachiocephalic vein 2 - 
   Superior venal cava 1 - 
Other anatomical findings 
   Tortuous cephalic/basilica veins 7 2 
   Vein depth >10mm 31 30 
   Cephalic vein ≥2 branches 15 16 
   Basilic vein ≥2 branches 10 12 
   High brachial artery bifurcation 4 3 
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Figure legends 
Figure 1. Method for the comparative analysis using arterial and venous vascular 
cross-sections. Ferumoxytol-enhanced MR angiography high-resolution steady-state 
(HRSS) coronal and transverse sections of the arm at the wrist, mid-forearm and 
elbow. Regions of interest were drawn for estimation of arterial and vein diameter and 
vein depth from skin surface. 
BA, brachial artery; BB, brachial vein bundle; BV, basilic vein; C, collateral vein; 
CV, cephalic vein; RA, radial artery 
 
Figure 2. Algorithm used to predict arteriovenous fistula outcome based on 
anatomical parameters evaluated with Duplex ultrasound and ferumoxytol-enhanced 
MR angiography 
 
Figure 3. Flowchart of recruitment and arteriovenous fistula outcomes 
Fe, ferumoxytol-enhanced; AVF, arteriovenous fistula; TCVC; tunneled central 
venous catheter 
 
Figure 4. Bland-Altman plots of inter-reader variability for ferumoxytol-enhanced 
MR angiography. A. Plot of arterial diameter measurements. The dark central line is 
the mean difference between the 2 analyses and the light outer lines show the limits of 
agreement (mean of the differences ± 1.96 SD). B. Plot of vein diameter 
measurements. C. Plot of vein depth measurements. There are no significant fixed or 
proportional biases as the lines of equality are within the confidence interval of the 
mean differences for all measurements. 
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Figure 5. Steady-state thick slab maximum intensity projection (MIP) coronal 
ferumoxytol-enhanced MR angiography images showing central veins abnormalities. 
A. Well-defined cephalic arch bilaterally before it enters the axillary vein to form the 
subclavian vein. B. Left cephalic arch stenosis near the confluence with the 
subclavian vein (arrow) and collateral vein formation (arrowhead). C. Left cephalic 
arch stenosis with collateral vein formation (arrow), cephalic vein stenosis 
(arrowhead) and cephalic vein valve (star). D. Left cephalic arch stenosis at the 
confluence with the subclavian vein (arrow). E. Tight stenosis at the junction of the 
right subclavian and brachiocephalic veins (arrow). F. Occluded right brachiocephalic 
vein (arrow). 
IJV, internal jugular vein; SCV, subclavian vein; BCV, brachiocephalic vein; SVC, 
superior vena cava  
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Supplementary Material 
Vascular mapping protocol 
 Veins were evaluated for diameter, patency, compressibility (Duplex 
ultrasound only), thrombus, course, side branches, depth from the skin surface, and 
linear length for future cannulation. The sites and length of any venous stenosis and 
the sites and sizes of vein branches were recorded. Venous mapping was performed 
with and without a venous pressure tourniquet in place. Arterial evaluation included 
measurement of the luminal diameter, patency, presence of inflow or outflow disease, 
calcifications (Duplex ultrasound only), and anatomic variants. Central arteries and 
veins were only assessed with ferumoxytol-enhanced MR angiography for the 
presence of stenosis or occlusion. Stenosis was defined as reduction of the luminal 
diameter of ≥50% and occlusion as complete absence of any flow signal. 
Ultrasound mapping 
 Duplex ultrasound of bilateral upper extremities was performed in real-time 
using a Philips iU22 color Duplex scanner (Philips Healthcare, Bothell, WA) with a 
5–17 MHz broadband linear-array transducer (Phillips L17-5). The participants were 
seated in front of the operator with the forearm resting on a stand. 
 Diameters of the radial artery, brachial artery, cephalic vein, and basilic vein 
at the arm and forearm level were measured. Blood flow measurements were 
performed with the angle between the Duplex beam and blood vessel axis between 
450–600, and the Duplex gate was set to cover the entire luminal cross-section. 
Transverse views were used for assessment of vessel diameter and longitudinal views 
for blood flow and calcifications. Images of the relevant gray scale, color, and 
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spectral Duplex waveforms were recorded and archived. Average Duplex ultrasound 
duration was 25 minutes for mapping of both arms. 
Arteriovenous fistula outcome 
 We determined AVF clinical maturation using criteria for usability during 
dialysis. Successful use was defined as clinical use of the AVF with two needles for at 
least 75% of dialysis sessions over a minimum continuous period of 30 days. For 
participants not on dialysis at the end of follow-up, ultrasound criteria for AVF 
maturation at 6 weeks (600 ml/min blood flow, 6 mm diameter, and <6 mm depth 




1. Vascular Access 2006 Work Group, Clinical practice guidelines for vascular 
access. Am J Kidney Dis. 2006;48 Suppl 1:S176-247. 
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Supplementary Table 1. Pulse sequence parameters for the ferumoxytol-enhanced 
MR angiography T1-weighted high-resolution 3D acquisitions 
Repetition time 2.88 msec 
Echo time 1.04 msec 
Flip angle 20 degrees 
Slice thickness Central vessels: 1.0 mm 
Upper arm: 0.7 mm 
Forearm: 0.6 mm 
Voxel dimensions Central vessels: 1.0 x 1.0 x 1.0 mm 
Upper arm: 0.7 x 0.7 x 0.7 mm 
Forearm: 0.6 x 0.6 x 0.6 mm 
Field of view Central vessels: 320 x 400 mm 
Upper arm: 300 x 480 mm 
Forearm: 180 x 400 mm 
Acquisition time 18 sec 
Signal averages 1 
Bandwidth 300 Hz/pixel 






Supplementary Table 2. Reasons for exclusion from the study (N =158) 
Contraindications to MRI (N=80) 
     29 claustrophobia 
     21 not fitting into the scanner due to obesity 
     19 metallic objects in the body 
     11 unable to lie flat (i.e. back pain, dyspnea) 
Frail or co-morbidities (N=52) 
     39 frail 
     8 active cancer 
     3 dementia 
     2 blind 
Allergies and other conditions (N=26) 
     11 multidrug allergies 
     7 asthma 
     6 allergic reaction to intravenous iron 










Supplementary Table 3. Interclass correlation coefficients to test consistency of 
agreement in ferumoxytol-enhanced MR angiography 




   RA (wrist) 0.90 (0.84 – 0.94) 0.95 (0.91 – 0.97) 
   RA (mid-forearm) 0.90 (0.83 – 0.94) 0.95 (0.91 – 0.97) 
   RA (elbow) 0.89 (0.85 – 0.93) 0.97 (0.94 – 0.98) 
   BA (elbow) 0.94 (0.88 – 0.97) 0.97 (0.94 – 0.98) 
   All arteries 0.90 (0.87 – 0.93) 0.95 (0.93 – 0.96) 
Vein diameter 
   CV (wrist) 0.95 (0.92 – 0.97) 0.98 (0.96 – 0.99) 
   CV (mid-forearm) 0.96 (0.94 – 0.98) 0.98 (0.97 – 0.99) 
   CV (elbow) 0.98 (0.97 – 0.99) 0.99 (0.98 – 1.00) 
   BV (elbow) 0.96 (0.93 – 0.98) 0.98 (0.96 – 0.99) 
   All veins 0.84 (0.78 – 0.88) 0.91 (0.88 – 0.93) 
Vein depth from skin surface 
   CV (wrist) 0.91 (0.85 – 0.95) 0.95 (0.92 – 0.98) 
   CV (mid-forearm) 0.99 (0.98 – 0.99) 0.99 (0.99 – 1.00) 
   CV (elbow) 0.99 (0.98 – 1.00) 0.99 (0.99 – 1.00) 
   BV (elbow) 0.95 (0.91 – 0.98) 0.98 (0.95 – 0.99) 
   All veins 0.92 (0.89 – 0.94) 0.96 (0.94 – 0.97) 
RA, radial artery; BA, brachial artery; CV, cephalic vein; BV, basilic vein 
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Supplementary Movie 1  
Maximum intensity projection (MIP) coronal ferumoxytol-enhanced MR angiography 
slices of the thorax showing normal arterial and venous central vasculature. Note the 
simultaneous arterial and venous enhancement with ferumoxytol-enhanced MR 
angiography due to the prolonged intravascular half-life of ferumoxytol. 
Supplementary Movie 2  
Maximum intensity projection (MIP) sagittal ferumoxytol-enhanced MR angiography 
slices of the forearm showing the anatomy, course, tortuosity, branches and proximity 
of vascular structures providing additional information to guide surgical decisions. 
Supplementary Movie 3  
Maximum intensity projection (MIP) transverse ferumoxytol-enhanced MR 
angiography slices of the mid-arm showing the diameter and course of the cephalic 
vein, basilic vein, brachial artery and concomitant brachial vein bundle throughout the 
length of the arm. 
Supplementary Movie 4  
Maximum intensity projection (MIP) coronal ferumoxytol-enhanced MR angiography 

























































59 mapping with Duplex US 
and Fe MR angiography 
8 no AVF creation 
  5 patient’s preference for TCVC 
  2 kidney transplant 
  1 conservative care 
51 AVF creation 
24 AVF success 
  12 unassisted maturation 
  6 assisted maturation 
  6 US maturation 
27 AVF failure 
  13 failure to mature 
  7 early failure 
  6 unsuccessful attempt 
  1 ligation for steal syndrome 
302 patients screened 
237 excluded 
  158 not fitting inclusion criteria 
    80 contraindications to MRI 
    52 frail or co-morbidities 
    26 allergies or iron overload 
  79 declined to participate 
6 excluded 
  4 failed Fe MR angiography 
  2 declined after signing consent 
65 patients consented 
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Figure 4 
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Figure 5 
 
